P21-Activated Kinase 5 Affects Cisplatin-induced Apoptosis and Proliferation in Hepatocellular Carcinoma Cells

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2015 Jan 7

PMID 25560489

Citations 14

Authors

Ding-Guo Zhang

Jinling Zhang

Lin-Lin Mao

Jin-Xia Wu

Wen-Jia Cao

Jun-Nian Zheng

Dong-Sheng Pei

Affiliations

Soon will be listed here.

Abstract

p21-Activated kinase 5 (PAK5) is the last identified member of the PAK family. The PAKs are highly conserved serine/threonine and effector proteins for Cdc42 and Rac and are essential in regulating cell motility and survival. Previous studies have demonstrated that PAK5 played a pivotal role in apoptosis, proliferation, cancer migration, and invasion. However, the biological function of PAK5 in hepatocellular carcinoma, as well as its underlying mechanism, still remains to be fully elucidated. In the present study, we demonstrated that PAK5 markedly inhibited cisplatin-induced apoptosis and promoted cell proliferation in hepatocellular carcinoma cells. Moreover, our results showed that overexpression of PAK5 contributed to cell cycle regulation. In order to elucidate the underlying mechanism of PAK5 on cisplatin-induced apoptosis and cell cycle regulation, we also examined the protein expressions of chk2 and p-chk2. In summary, our study investigated the role of PAK5 in cisplatin-induced cellular processes and provided evidence of its underlying mechanism.

Citing Articles

Hyperactivation of p21-Activated Kinases in Human Cancer and Therapeutic Sensitivity.

Sankaran D, Amjesh R, Paul A, George B, Kala R, Saini S Biomedicines. 2023; 11(2).

PMID: 36830998 PMC: 9953343. DOI: 10.3390/biomedicines11020462.

P-21 Activated Kinases in Liver Disorders.

Qiu X, Xu H, Wang K, Gao F, Xu X, He H Cancers (Basel). 2023; 15(2).

PMID: 36672500 PMC: 9857091. DOI: 10.3390/cancers15020551.

Minor Kinases with Major Roles in Cytokinesis Regulation.

Sechi S, Piergentili R, Giansanti M Cells. 2022; 11(22).

PMID: 36429067 PMC: 9688779. DOI: 10.3390/cells11223639.

RHO GTPase family in hepatocellular carcinoma.

Wang T, Rao D, Yu C, Sheng J, Luo Y, Xia L Exp Hematol Oncol. 2022; 11(1):91.

PMID: 36348464 PMC: 9644471. DOI: 10.1186/s40164-022-00344-4.

MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.

Li T, Mou J, Pan Y, Huo F, Du W, Liang J J Biomed Sci. 2021; 28(1):56.

PMID: 34340705 PMC: 8327419. DOI: 10.1186/s12929-021-00752-4.

References

Zcharia E, Atzmon R, Nagler A, Shimoni A, Peretz T, Vlodavsky I . Inhibition of matrix metalloproteinase-2 by halofuginone is mediated by the Egr1 transcription factor. Anticancer Drugs. 2012; 23(10):1022-31. DOI: 10.1097/CAD.0b013e328357d186. View

Cotteret S, Jaffer Z, Beeser A, Chernoff J . p21-Activated kinase 5 (Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylating BAD. Mol Cell Biol. 2003; 23(16):5526-39. PMC: 166342. DOI: 10.1128/MCB.23.16.5526-5539.2003. View

Umit Unal O, Yilmaz A, Yavuzsen T, Akman T, Ellidokuz H . Intra-peritoneal cisplatin combined with intravenous paclitaxel in optimally debulked stage 3 ovarian cancer patients: an Izmir Oncology Group study. Asian Pac J Cancer Prev. 2014; 15(15):6165-9. DOI: 10.7314/apjcp.2014.15.15.6165. View

Li J, Wang Y, Song Y, Fu Z, Yu W . miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells. Mol Cancer. 2014; 13:193. PMC: 4158130. DOI: 10.1186/1476-4598-13-193. View

Gong W, An Z, Wang Y, Pan X, Fang W, Jiang B . P21-activated kinase 5 is overexpressed during colorectal cancer progression and regulates colorectal carcinoma cell adhesion and migration. Int J Cancer. 2009; 125(3):548-55. DOI: 10.1002/ijc.24428. View

Fang Z, Jiang B, Gu X, Zhao B, Ge R, Zhang F . P21-activated kinase 5 plays essential roles in the proliferation and tumorigenicity of human hepatocellular carcinoma. Acta Pharmacol Sin. 2013; 35(1):82-8. PMC: 4075737. DOI: 10.1038/aps.2013.31. View

Citri A, Yarden Y . EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006; 7(7):505-16. DOI: 10.1038/nrm1962. View

Dart A, Wells C . P21-activated kinase 4--not just one of the PAK. Eur J Cell Biol. 2013; 92(4-5):129-38. DOI: 10.1016/j.ejcb.2013.03.002. View

Antoni L, Sodha N, Collins I, Garrett M . CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?. Nat Rev Cancer. 2007; 7(12):925-36. DOI: 10.1038/nrc2251. View

10.

Li D, Yao X, Zhang P . The overexpression of P21-activated kinase 5 (PAK5) promotes paclitaxel-chemoresistance of epithelial ovarian cancer. Mol Cell Biochem. 2013; 383(1-2):191-9. DOI: 10.1007/s11010-013-1767-7. View

11.

Liang X, Reed E, Yu J . Protein phosphatase 2A interacts with Chk2 and regulates phosphorylation at Thr-68 after cisplatin treatment of human ovarian cancer cells. Int J Mol Med. 2006; 17(5):703-8. View

12.

Dan C, Nath N, Liberto M, Minden A . PAK5, a new brain-specific kinase, promotes neurite outgrowth in N1E-115 cells. Mol Cell Biol. 2002; 22(2):567-77. PMC: 139731. DOI: 10.1128/MCB.22.2.567-577.2002. View

13.

Shuck S, Short E, Turchi J . Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology. Cell Res. 2008; 18(1):64-72. PMC: 2432112. DOI: 10.1038/cr.2008.2. View

14.

Wen Y, Wang X, Pei D, Zheng J . p21-Activated kinase 5: a pleiotropic kinase. Bioorg Med Chem Lett. 2013; 23(24):6636-9. DOI: 10.1016/j.bmcl.2013.10.051. View

15.

Damia G, Filiberti L, Vikhanskaya F, Carrassa L, Taya Y, DIncalci M . Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia. 2001; 3(1):10-6. PMC: 1505020. DOI: 10.1038/sj.neo.7900122. View

16.

Wang X, Gong W, Qing H, Geng Y, Wang X, Zhang Y . p21-activated kinase 5 inhibits camptothecin-induced apoptosis in colorectal carcinoma cells. Tumour Biol. 2010; 31(6):575-82. DOI: 10.1007/s13277-010-0071-3. View

17.

Gu J, Li K, Li M, Wu X, Zhang L, Ding Q . A role for p21-activated kinase 7 in the development of gastric cancer. FEBS J. 2012; 280(1):46-55. DOI: 10.1111/febs.12048. View

18.

DAnzeo M, Faloppi L, Scartozzi M, Giampieri R, Bianconi M, Del Prete M . The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment. Molecules. 2014; 19(5):6393-406. PMC: 6271763. DOI: 10.3390/molecules19056393. View

19.

Pandey A, Dan I, Kristiansen T, Watanabe N, Voldby J, Kajikawa E . Cloning and characterization of PAK5, a novel member of mammalian p21-activated kinase-II subfamily that is predominantly expressed in brain. Oncogene. 2002; 21(24):3939-48. DOI: 10.1038/sj.onc.1205478. View

20.

Vitale I, Galluzzi L, Vivet S, Nanty L, Dessen P, Senovilla L . Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway. PLoS One. 2007; 2(12):e1337. PMC: 2131784. DOI: 10.1371/journal.pone.0001337. View